What question did this study set out to answer?

To compare infliximab exposure and clinical outcomes from intravenous to subcutaneous therapy in patients with inflammatory bowel disease.

P0902Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure independent of comedication with thiopurines (SHUFFLE study)

View Full Paper

Ask AI

Bookmark

To compare infliximab exposure and clinical outcomes from intravenous to subcutaneous therapy in patients with inflammatory bowel disease.
Conducted a single-centre, prospective study with 38 adult IBD patients in clinical remission.
Patients switched from IV to SC infliximab on a biweekly dosing schedule for 24 weeks.
Measured pharmacokinetic parameters, including Area Under the Concentration-time curves (AUCs) and trough levels.
Assessed the formation of anti-drug antibodies (ADAbs) and quality of life using IBDQ-NL scores.
Mean AUCs were comparable between intravenous and subcutaneous administration (27,662 vs 29,320 mg·h/L).
Subcutaneous infliximab significantly increased trough levels compared to intravenous (4.6 vs 16.1 mg/L).
The time burden for application decreased by a median of 9.3 hours over six months.
Quality of life scores improved from 189 to 197.
97% of participants continued treatment with subcutaneous infliximab after six months.

No takes yet. Share an insight, caveat, or question.

Prospective study compares drug exposure and outcomes of switching from IV to SC infliximab in IBD patients, suggesting improved quality of life.

Ven et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Prospective study compares drug exposure and outcomes of switching from IV to SC infliximab in IBD patients, suggesting improved quality of life.